SHENZHEN, China, June 16, 2026 /PRNewswire/ -- Shell Recharge and SINEXCEL (300693.SZ) officially signed a Memorandum of Understanding (MoU) and inaugurated the Shell Recharge–SINEXCEL Joint...
SHENZHEN, China, June 16, 2026 /PRNewswire/ -- Shell Recharge and SINEXCEL (300693.SZ) officially signed a Memorandum of Understanding (MoU) and inaugurated the Shell Recharge–SINEXCEL Joint...
HONG KONG, June 16, 2026 /PRNewswire/ -- Tencent Cloud, the cloud business of global leading technology company Tencent, today announced a strategic partnership with...
MILWAUKEE, June 16, 2026 (GLOBE NEWSWIRE) -- Fiserv, Inc. (NASDAQ: FISV) (the “Company”), a leading global provider of payments and financial services technology solutions, today announced the commencement of tender offers to purchase for cash any and all of the senior notes issued by the Company listed in the table below (collectively, the “Notes”). The tender offers (the “Offers”) are being made pursuant to the Offer to Purchase, dated June 16, 2026 (the “Offer to Purchase”).
Please see below information about transactions made under the second tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).
MUMBAI, India, June 16, 2026 /PRNewswire/ -- InCred Capital, the institutional, wealth and asset management arm of InCred Group, today announced the launch of...
REYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 22,666,667 of its ordinary shares at an offering price of $3.75 per share. All ordinary shares to be sold in the Offering will be offered by Alvotech. The Offering is expected to close on or about June 17, 2026, subject to satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to an additional 3,400,000 ordinary shares at the public offering price, less underwriting discounts and commissions. Before deducting the underwriting discounts and commissions and offering expenses, the Company expects to receive total gross proceeds of approximately $85 million from the Offering, or approximately $98 million if the underwriters exercise in full their option to purchase additional shares.
Rhode Island Becomes Zum's 18th State as Company Expands Northeast PresenceREDWOOD CITY, Calif., June 15, 2026 /PRNewswire/ -- Scituate School Department and Johnston Public...
MORGANTOWN, W.Va., June 15, 2026 /PRNewswire/ -- Prominently featured in The Inner Circle, Haider Jaffrey, DDS is acknowledged as a Pinnacle Lifetime Member for his...
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”), of the important June 23, 2026 lead plaintiff deadline.
Functional ingredient innovator outpaces supplement industry growth through proprietary ingredient development, fermentation technology, and expanding global partnershipsBOISE, Idaho, June 15, 2026 /PRNewswire/ -- NNB Nutrition,...